JP2014531461A5 - - Google Patents

Download PDF

Info

Publication number
JP2014531461A5
JP2014531461A5 JP2014533645A JP2014533645A JP2014531461A5 JP 2014531461 A5 JP2014531461 A5 JP 2014531461A5 JP 2014533645 A JP2014533645 A JP 2014533645A JP 2014533645 A JP2014533645 A JP 2014533645A JP 2014531461 A5 JP2014531461 A5 JP 2014531461A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
inhibitor
active agent
combination
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014533645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014531461A (ja
JP6224597B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/057085 external-priority patent/WO2013049045A1/en
Publication of JP2014531461A publication Critical patent/JP2014531461A/ja
Publication of JP2014531461A5 publication Critical patent/JP2014531461A5/ja
Application granted granted Critical
Publication of JP6224597B2 publication Critical patent/JP6224597B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014533645A 2011-09-27 2012-09-25 グリオーマを処置するための組成物及び方法 Active JP6224597B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161539779P 2011-09-27 2011-09-27
US61/539,779 2011-09-27
PCT/US2012/057085 WO2013049045A1 (en) 2011-09-27 2012-09-25 Compositions and methods of treating gliomas

Publications (3)

Publication Number Publication Date
JP2014531461A JP2014531461A (ja) 2014-11-27
JP2014531461A5 true JP2014531461A5 (cg-RX-API-DMAC7.html) 2015-12-03
JP6224597B2 JP6224597B2 (ja) 2017-11-01

Family

ID=47996335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014533645A Active JP6224597B2 (ja) 2011-09-27 2012-09-25 グリオーマを処置するための組成物及び方法

Country Status (5)

Country Link
US (1) US9757424B2 (cg-RX-API-DMAC7.html)
EP (1) EP2760473A1 (cg-RX-API-DMAC7.html)
JP (1) JP6224597B2 (cg-RX-API-DMAC7.html)
CN (1) CN103930132A (cg-RX-API-DMAC7.html)
WO (1) WO2013049045A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
WO2014023329A1 (en) * 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
WO2016062289A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 帕罗西汀药物用于制备治疗癌症的医药组合物中的用途
KR101773244B1 (ko) * 2015-02-27 2017-09-01 이화여자대학교 산학협력단 암로디핀을 포함하는 뇌종양 예방 또는 치료용 약학적 조성물
US10675257B2 (en) 2015-07-31 2020-06-09 Inflectis Bioscience Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent
CN107088194A (zh) * 2016-02-17 2017-08-25 深圳市坤健创新药物研究院 药物氨氯地平的新用途
WO2017190028A1 (en) * 2016-04-29 2017-11-02 Autotelic Llc Methods for treating cancers using ace inhibitors, arb, or celecoxib and olmesartan
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
KR102005887B1 (ko) * 2016-12-09 2019-07-31 서울대학교산학협력단 뇌종양의 예방 또는 치료용 약학 조성물
AU2019242628A1 (en) 2018-03-26 2020-09-24 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
CN112189013A (zh) * 2018-05-25 2021-01-05 细胞内治疗公司 有机化合物
US12396992B2 (en) 2019-01-07 2025-08-26 Intra-Cellular Therapies, Inc. Organic compounds
CN111773377B (zh) * 2019-04-04 2023-03-14 中南大学 阿尼芬净在制备抗肿瘤药物中的应用及抗肿瘤药物
CN110876800B (zh) * 2019-11-18 2023-06-27 中南大学 米卡芬净在制备抗肿瘤药物中的应用及抗肿瘤药物
CN110960533A (zh) * 2019-12-31 2020-04-07 苏州青雅启瑞生物科技有限公司 马尼地平联用替莫唑胺及其药物组合在制备用于治疗脑胶质瘤的药物中的应用
US20210315880A1 (en) 2020-03-20 2021-10-14 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease
CN111803497A (zh) * 2020-09-02 2020-10-23 中国科学院昆明动物研究所 乐卡地平类药物在制备治疗人神经胶质瘤药物中的用途
US20230355568A1 (en) * 2020-10-28 2023-11-09 National University Corporation Tokai National Higher Education And Research System Therapeutic agent for malignant mesothelioma and method for selecting patient having malignant mesothelioma
IL307949A (en) * 2021-05-07 2023-12-01 Lilly Co Eli 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridine-2-ylg-benzamide hemisuccinate masked flavor compounds, and an orodispersible tablet consisting of the same
KR102893290B1 (ko) * 2021-12-17 2025-12-01 숙명여자대학교산학협력단 뇌종양 치료를 위한 글리세오플빈 병용요법
WO2023113538A1 (ko) * 2021-12-17 2023-06-22 숙명여자대학교산학협력단 뇌종양 치료를 위한 글리세오플빈 병용요법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1605894A2 (en) * 2003-03-05 2005-12-21 PR Pharmaceuticals Oxytocin controlled release formulations and methods of using same
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
EP1851197A2 (en) * 2005-02-09 2007-11-07 Microbia, Inc. Phenylazetidinone derivatives
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
EP1940461B1 (en) * 2005-11-02 2014-01-08 Duke University Concurrent chemotherapy and immunotherapy
WO2007111733A2 (en) * 2005-12-16 2007-10-04 Genentech, Inc. Method for diagnosing, prognosing and treating glioma
TWI494134B (zh) * 2006-06-20 2015-08-01 Siegfried Generics Int Ag 含有坎地沙坦酯的組成物、錠劑和顆粒及該錠劑的製造方法
MX2009000385A (es) 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
EP1958637A1 (en) * 2007-02-14 2008-08-20 Revotar Biopharmaceuticals AG Pharmaceutical composition for the treatment of IL-8 mediated diseases
JP2010518147A (ja) * 2007-02-16 2010-05-27 ノバルティス アーゲー 有機化合物の使用
TWI473610B (zh) 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因(diacerein)之醫藥組合物

Similar Documents

Publication Publication Date Title
JP2014531461A5 (cg-RX-API-DMAC7.html)
JP6224597B2 (ja) グリオーマを処置するための組成物及び方法
KR102719738B1 (ko) 승모판 질환으로 인한 무증상 심부전이 있는 환자에서 심장 크기의 감소 및/또는 임상적 증상 개시의 지연을 위한 피모벤단의 용도
JP2010511621A5 (cg-RX-API-DMAC7.html)
RU2014111474A (ru) Способы лечения сердечно-сосудистых нарушений
AU2010200833B2 (en) Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
JP2014515402A5 (cg-RX-API-DMAC7.html)
JP2012525323A5 (cg-RX-API-DMAC7.html)
JP2020506180A5 (cg-RX-API-DMAC7.html)
CA2439920A1 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
CL2011000625A1 (es) Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida.
RU2019126749A (ru) Композиции для лечения гипертензии
AU2002336267A1 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
CN101300030A (zh) 血管紧张素ⅱ受体阻滞剂、钙通道阻滞剂和另一活性物质的组合产品
RU2001132073A (ru) Фармацевтическая композиция для предотвращения, лечения или ингибирования развития простой ретинопатии и препролиферирующей ретинопатии
US10111858B2 (en) Pharmaceutical for prophylaxis or treatment of hypertension
CN100372539C (zh) 用于治疗恶性疾病、包含双膦酸类化合物、cox-2抑制剂和紫杉醇的组合的药物组合物
JP2016520135A5 (cg-RX-API-DMAC7.html)
US20040116510A1 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
CN108778334A (zh) 用于治疗肾脏疾病的药物
JP2010519235A5 (cg-RX-API-DMAC7.html)
CN1589154A (zh) 含有血管紧张肽ii受体拮抗剂的药用组合物
JP2010031006A5 (cg-RX-API-DMAC7.html)
US20100292335A1 (en) Use of organic compounds
Liederer Case study: Olmesartan Medoxomil: a prodrug of olmesartan